74 participants
Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2020-09-09
- Start Date:
- 2020-09-15
- Completion:
- 2021-12-30
Conditions
- NSCLC
Interventions
- DRUG
No Results Yet